The low-expression variant of FABP4 is associated with cardiovascular disease in type 1 diabetes
Emma H. Dahlström(University of Helsinki), Per‐Henrik Groop(University of Helsinki), Nicoline Uglebjerg(Steno Diabetes Centers), Niina Sandholm(University of Helsinki), Valma Harjutsalo(Research Council of Finland), Lena M. Thorn(University of Helsinki), Jani Saksi(University of Helsinki), Perttu J. Lindsberg(University of Helsinki), Tarunveer S. Ahluwalia(Steno Diabetes Centers), Peter Rossing(Steno Diabetes Centers), Carol Forsblom(University of Helsinki)
Cited by 0
Related Papers
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
|New England Journal of Medicine|2024|1.5k